As a researcher in genetics, I have been involved in therapeutic gene transfer since 1993. Of the many aspects of retroviral vector development I have now focused my interest in the understanding of retroviral biology in order to modify particles to enable the delivery of various types of RNAs. Besides, and as an MD, I contribute to French regulatory committees evaluating gene therapy biosafety. Recently, I have started the study of some molecular aspects in HCV particle formation.